Melanoma/Skin Cancer News

The FDA today approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600-positive advanced melanoma, according to a manufacturer-issued press release.

As an oncologist who treats melanoma, Antoni Ribas, MD, PhD, typically views skin color from a strictly scientific perspective.

Baseline characteristics such as albumin, creatinine and BMI are useful biomarkers to aid in the management of patients with melanoma who are undergoing pembrolizumab treatment.

The Society for Immunotherapy of Cancer announced the results of its 2020 election, conducted this spring.

Janice M. Mehnert, MD, has been appointed associate director for clinical research at NYU Langone Health’s Perlmutter Cancer Center.

The FDA approved pembrolizumab for treatment of recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

Treatment with sonidegib was safe and effective in patients with locally advanced basal cell carcinoma, according to study results presented at the American Academy of Dermatology virtual meeting.

Adjuvant immunotherapy conferred a significant OS benefit among patients with resected stage IIIC melanoma, according to study results presented at American Association for Cancer Research Virtual Annual Meeting II.

Use of vitamin D supplements appeared to reduce risk for colitis among patients with cancer treated with immune checkpoint inhibitors, according to results of a retrospective study published in Cancer.

Socioeconomic disparities may lead to a lower awareness of melanoma and its dangers, especially among those who are Hispanic, according to a cross-sectional study presented at the American Academy of Dermatology virtual meeting.